Observational studyImmunity, inflammation and disease2025
The Importance of Pan-Immune-Inflammation Value Score in Locally Advanced Rectal Cancer.
Observational study in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic significance of integrating pretreatment biopsy-derived Immunoscore and Pan-Immune-Inflammation value in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- The Role of the Delta Neutrophil Index, Pan-Immune Inflammation Value and Other Hematologic Inflammatory Parameters in the Preliminary Diagnosis of Tubal Ectopic Pregnancy.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimIn this study, we aimed to observe the prognostic significance of the pan-immune-inflammation value (PIV) score calculated at the time of diagnosis in patients with locally advanced rectal cancer, as well as its effect on treatment response, survival, and prognosis. MATERIAL AND
methodThis retrospective, single-center observational study was designed to analyze patients with nonmetastatic (stages II-III) rectal cancer who received neoadjuvant treatment, categorized into two groups: PIV-L (n = 67, 50%) and PIV-H (n = 67, 50%). The median PIV score was used for cutoff determination. Survival analysis was applied. Univariate and multivariate Cox regression analyses were used to determine prognostic factors.
resultsPreoperative clinical lymph node status (p = 0.011), liver metastasis (p = 0.028), carcinoembryonic antigen (CEA; p = 0.013), and cancer antigen 19.9 (CA19.9; p = 0.040) levels; pathological complete response (p = 0.035); tumor regression score (p = 0.030); postoperative lymph node status (p = 0.019); tumor deposits (p = 0.035); and budding (p = 0.043) were statistically different between the groups. The 5- and 10-year overall survival (OS) rates were 77% versus 69% and 62% versus 38% in the PIV-L and PIV-H groups, respectively (p = 0.032). While the PIV score was prognostic for OS in univariate analysis (HR: 1.85, 95% CI: 1.04-3.31, p = 0.035), a result of insignificance was obtained in multivariate analysis (HR: 1.76, 95% CI: 0.98-3.01 p = 0.056). The 5- and 10-year disease-free survival (DFS) rates were 67% versus 54% and 56% versus 39% in the PIV-L and PIV-H groups, respectively, with the PIV-H group showing a statistically significantly lower rate (p = 0.048). For DFS, the PIV score was found to be a statistically insignificant prognostic factor in univariate analysis (HR: 0.052, 95% CI: 0.99-2.86, p = 0.052) and recognized as an independent prognostic factor in multivariate analysis (HR: 1.87, 95% CI: 1.08-3.26, p = 0.026).
conclusionA higher pretreatment PIV score was associated with poorer clinicopathological features, a worse treatment response, lower survival rates, and a poor prognosis for DFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.